Gepirone

Jump to: navigation, search
Gepirone
Gepirone.png
Clinical data
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: uncontrolled
Pharmacokinetic data
Elimination half-life2-3 hours
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H29N5O2
Molar mass359.46586 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Gepirone

Articles

Most recent articles on Gepirone

Most cited articles on Gepirone

Review articles on Gepirone

Articles on Gepirone in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Gepirone

Images of Gepirone

Photos of Gepirone

Podcasts & MP3s on Gepirone

Videos on Gepirone

Evidence Based Medicine

Cochrane Collaboration on Gepirone

Bandolier on Gepirone

TRIP on Gepirone

Clinical Trials

Ongoing Trials on Gepirone at Clinical Trials.gov

Trial results on Gepirone

Clinical Trials on Gepirone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Gepirone

NICE Guidance on Gepirone

NHS PRODIGY Guidance

FDA on Gepirone

CDC on Gepirone

Books

Books on Gepirone

News

Gepirone in the news

Be alerted to news on Gepirone

News trends on Gepirone

Commentary

Blogs on Gepirone

Definitions

Definitions of Gepirone

Patient Resources / Community

Patient resources on Gepirone

Discussion groups on Gepirone

Patient Handouts on Gepirone

Directions to Hospitals Treating Gepirone

Risk calculators and risk factors for Gepirone

Healthcare Provider Resources

Symptoms of Gepirone

Causes & Risk Factors for Gepirone

Diagnostic studies for Gepirone

Treatment of Gepirone

Continuing Medical Education (CME)

CME Programs on Gepirone

International

Gepirone en Espanol

Gepirone en Francais

Business

Gepirone in the Marketplace

Patents on Gepirone

Experimental / Informatics

List of terms related to Gepirone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Gepirone (Ariza, Variza; BMY-13,805, ORG-13,011) is an antidepressant and anxiolytic of the azapirone class. Like other azapirones, it acts as a selective partial agonist of the 5-HT1A receptor. Gepirone was under development in the U.S. in an extended release form, but despite completing phase III clinical trials, it failed to pass the drug approval process. As a result, gepirone, despite already having brand names picked out, did not manage to reach the pharmaceutical market.

Gepirone was originally developed by Bristol-Myers Squibb, but was out-licensed to Fabre-Kramer in 1993. The U.S. Food and Drug Administration (FDA) rejected approval for gepirone in 2004. It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2004. However, in 2007 it once again failed to convince the FDA of its qualities for treating anxiety and depression. There have been no updates on gepirone since.

Synthesis

Gepirone synth.png

Ormaza, V. A.; 1986, ES 8606333 .

References


Linked-in.jpg